EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Multizentrische StudieOpen Access · CC BY-NC 4.0

Venetoclax in Pediatric and Young Adult Patients With Relapsed/Refractory Solid Tumors: Results of a Phase 1 Study

Daniel A Morgenstern, Giuseppe Barone, Nadege Corradini, Sara M Federico iD, Christian Flotho, Nicolas U Gerber, Seong Lin Khaw, Margaret E Macy iD, Andrew E Place iD, Kieuhoa T Vo, Mohamed Badawi, Xin Chen und 7 weitere

Pediatric Blood & Cancer · 2026-05 · 73 (5)

DOI: 10.1002/1545-5017.70178 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Pediatric Blood & Cancer, online erschienen am 13.03.2026. Verfasst von Daniel A Morgenstern und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Paediatrics, Hospital for Sick Children & University of Toronto, Toronto, Ontario, Canada. Hauptthemen laut MEDLINE: Sulfonamides, Bridged Bicyclo Compounds, Heterocyclic, Neoplasm Recurrence, Local, Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Genentech, AbbVie.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

B‐cell lymphoma 2 (BCL‐2) is overexpressed in certain solid tumors (including neuroblastoma), representing a promising target. Venetoclax is a first‐in‐class, oral, highly selective BCL‐2 inhibitor. We report safety, pharmacokinetics, and efficacy of venetoclax in children and young adults with relapsed/refractory solid tumors. Procedure M13‐833 (NCT03236857) was a Phase 1, open‐label, global, two‐part study. Patients received age‐/weight‐adjusted venetoclax (400 or 800 mg/day adult equivalent dose [AED]) continuously or intermittently (Days 1–10 of 21‐day cycles) as monotherapy or with cyclophosphamide and topotecan (Cy–Topo; Cy 250 mg/m 2 /day + Topo 0.75 mg/m 2 /day; intravenously Days 1–5) and myeloid growth factor support. Primary objectives included safety and pharmacokinetic assessments of venetoclax; secondary objectives included efficacy.

Results

Fifty‐nine patients in the neuroblastoma ( n = 36; median age: 8 years [range: 1–17]) and solid tumor cohorts ( n = 23; median age: 16 years [range: 3–24]) were assessed. Grade ≥3 treatment‐emergent adverse events (TEAEs) occurred in 35/36 (97%) and 21/23 (91%) neuroblastoma and solid tumor patients, respectively; febrile neutropenia was the most common serious TEAE (neuroblastoma 69%; solid tumors 57%). TEAEs leading to discontinuation of venetoclax occurred in 17% (neuroblastoma) and 9% (solid tumors) of patients. No events of tumor lysis syndrome were observed. Peak venetoclax concentrations ( T max ) occurred 4–6 h post‐dose; exposure was comparable across age/weight subgroups. Objective response rates were 31% (neuroblastoma) and 22% (solid tumors).

Conclusions

Recommended Phase 2 dose of venetoclax was 800 mg/day AED (Days 1–10 of 21‐day cycles). Venetoclax combined with Cy–Topo chemotherapy had a predictable safety profile and showed modest clinical activity in these cohorts.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SulfonamidesBridged Bicyclo Compounds, HeterocyclicNeoplasm Recurrence, LocalNeoplasmsAntineoplastic AgentsDrug Resistance, NeoplasmHumansFemaleChildMaleAdolescentChild, PreschoolYoung AdultInfantAdultFollow-Up StudiesTopotecanAntineoplastic Combined Chemotherapy ProtocolsPrognosis

Stichwörter der Autor:innen

BCL‐2Phase 1neuroblastomapediatricsolid tumorsvenetoclax

Substanzen

SulfonamidesBridged Bicyclo Compounds, HeterocyclicvenetoclaxTopotecanAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Paediatrics, Hospital for Sick Children & University of Toronto, Toronto, Ontario, Canada.
  • Department of Paediatric Oncology, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK.
  • Hematology and Oncology Pediatric Institute, Léon Bérard Center, Lyon, France.
  • Department of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
  • Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, Faculty of Medicine, University Medical Center Freiburg, University of Freiburg, Freiburg, Germany.
  • Department of Oncology, University Children's Hospital, Zurich, Switzerland.

ORCID-Profile: Sara M Federico, Margaret E Macy, Andrew E Place

Förderung

  • Genentech
  • AbbVie

Zitieren

APA

Morgenstern, D. A., Barone, G., Corradini, N., Federico, S. M., Flotho, C., Gerber, N. U., Khaw, S. L., Macy, M. E., Place, A. E., Vo, K. T., Badawi, M., Chen, X., Luo, A., Rocco, M. A., Ross, J. A., Scherer, F., Sunkersett, G., Onishi, M., & Goldsmith, K. C. (2026). Venetoclax in Pediatric and Young Adult Patients With Relapsed/Refractory Solid Tumors: Results of a Phase 1 Study. Pediatric Blood & Cancer, 73(5). https://doi.org/10.1002/1545-5017.70178

Vancouver

Morgenstern DA, Barone G, Corradini N, Federico SM, Flotho C, Gerber NU, et al. Venetoclax in Pediatric and Young Adult Patients With Relapsed/Refractory Solid Tumors: Results of a Phase 1 Study. Pediatric Blood & Cancer. 2026;73(5). doi:10.1002/1545-5017.70178

BibTeX
@article{Morgenstern2026,
  author = {Morgenstern, Daniel A and Barone, Giuseppe and Corradini, Nadege and Federico, Sara M and Flotho, Christian and Gerber, Nicolas U and Khaw, Seong Lin and Macy, Margaret E and Place, Andrew E and Vo, Kieuhoa T and Badawi, Mohamed and Chen, Xin and Luo, Adam and Rocco, Mark A and Ross, Jeremy A and Scherer, Frank and Sunkersett, Gauri and Onishi, Maika and Goldsmith, Kelly C},
  title = {Venetoclax in Pediatric and Young Adult Patients With Relapsed/Refractory Solid Tumors: Results of a Phase 1 Study},
  journal = {Pediatric Blood & Cancer},
  year = {2026},
  volume = {73},
  number = {5},
  doi = {10.1002/1545-5017.70178}
}
Kostenlos starten →